nach oben

Zeitschrift für Pneumologie

Erschienen in:

09.01.2017 | COPD | CME

Übersicht COPD

Diagnostik, Prävention und Therapie

verfasst von: Dr. B. Beutel, T. Greulich, C. Vogelmeier, A. Rembert Koczulla

Erschienen in: Zeitschrift für Pneumologie | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die chronisch obstruktive Lungenerkrankung (COPD) ist durch eine nicht vollständig reversible Atemflusseinschränkung charakterisiert und mit hoher Morbidität, Mortalität und Kosten verbunden. Die vermeidbare, typischerweise progredient verlaufende, aber behandelbare Erkrankung wird als pulmonale Komponente einer chronischen Multimorbidität angesehen. Die Diagnosestellung erfolgt anhand von Klinik und Spirometrie. Als bedeutendster Risikofaktor gilt inhalativer Zigarettenrauch, weshalb in der Behandlungsstrategie eine absolute Tabakkarenz die wichtigste präventive Maßnahme der COPD darstellt. Multimodale pharmakologische und nichtpharmakologische Therapieansätze sollen die Lebensqualität und die Lungenfunktion verbessern sowie Exazerbationen verhindern. Für eine gut selektionierte Patientengruppe mit Lungenemphysem können bronchoskopische Maßnahmen in ausgewiesenen Zentren eine mögliche Behandlungsoption darstellen.

Murray CJ, Lopez AD (2013) Measuring the global burden of disease. N Engl J Med 369(5):448–457CrossRefPubMed

Rosenbaum L, Lamas D (2011) Facing a „slow-motion disaster“ – the UN meeting on noncommunicable diseases. N Engl J Med 365(25):2345–2348CrossRefPubMed

Global Initiative for Chronic Obstructive Lung Disease (2016) GOLD 2017 report. www.goldcopd.org

Raherison C, Girodet PO (2009) Epidemiology of COPD. Eur Respir Rev 18(114):213–221CrossRefPubMed

Tuder RM, Petrache I (2012) Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest 122(8):2749–2755CrossRefPubMedPubMedCentral

Kotecha SJ et al (2013) Effect of preterm birth on later FEV1: a systematic review and meta-analysis. Thorax 68(8):760–766CrossRefPubMed

Brostrom EB et al (2010) Obstructive lung disease in children with mild to severe BPD. Respir Med 104(3):362–370CrossRefPubMed

Greulich T et al (2013) Alpha1-antitrypsin deficiency – diagnostic testing and disease awareness in Germany and Italy. Respir Med 107(9):1400–1408CrossRefPubMed

Greulich T, Vogelmeier CF (2015) Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. Ther Adv Respir Dis 10(1):72–84. doi:10.1177/1753465815602162 CrossRefPubMed

10.

Watz H et al (2009) Physical activity in patients with COPD. Eur Respir J 33(2):262–272CrossRefPubMed

11.

Kessler R et al (2011) Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 37(2):264–272CrossRefPubMed

12.

Celli BR et al (2015) An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur Respir J 45(4):879–905CrossRefPubMed

13.

Vanfleteren LE et al (2013) Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187(7):728–735CrossRefPubMed

14.

Dursunoglu N et al (2015) Severity of coronary atherosclerosis in patients with COPD. Clin Respir J. doi:10.1111/crj.12412 PubMed

15.

Barnes PJ, Celli BR (2009) Systemic manifestations and comorbidities of COPD. Eur Respir J 33(5):1165–1185CrossRefPubMed

16.

Vanfleteren LE (2015) Does COPD stand for „COmorbidity with Pulmonary Disease“? Eur Respir J 45(1):14–17CrossRefPubMed

17.

Rizkallah J, Man SF, Sin DD (2009) Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest 135(3):786–793CrossRefPubMed

18.

Shapira-Rootman M et al (2015) The prevalence of pulmonary embolism among patients suffering from acute exacerbations of chronic obstructive pulmonary disease. Emerg Radiol 22(3):257–260CrossRefPubMed

19.

Chen CY, Liao KM (2015) The incidence of deep vein thrombosis in Asian patients with chronic obstructive pulmonary disease. Medicine (Baltimore) 94(44):e1741CrossRef

20.

Borvik T et al (2016) COPD and risk of venous thromboembolism and mortality in a general population. Eur Respir J 47(2):473–481CrossRefPubMed

21.

Hobbs BD et al (2014) Pneumothorax risk factors in smokers with and without chronic obstructive pulmonary disease. Ann Am Thorac Soc 11(9):1387–1394CrossRefPubMedPubMedCentral

22.

Fabbri LM, Beghe B, Agusti A (2012) COPD and the solar system: introducing the chronic obstructive pulmonary disease comorbidome. Am J Respir Crit Care Med 186(2):117–119CrossRefPubMed

23.

Zvezdin B et al (2009) A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 136(2):376–380CrossRefPubMed

24.

Vestbo J et al (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187(4):347–365CrossRefPubMed

25.

Vogelmeier CF et al (2015) Changes in GOLD: today and tomorrow. Lancet Respir Med 3(6):424–426CrossRefPubMed

26.

Anthonisen NR et al (1994) Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272(19):1497–1505CrossRefPubMed

27.

Cahill K, Stead LF, Lancaster T (2007) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev:. doi:10.1002/14651858.cd006103.pub2

28.

Cahill K, Stead LF, Lancaster T (2008) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev:. doi:10.1002/14651858.cd006103.pub3 PubMedCentral

29.

Halpern SD et al (2015) Randomized trial of four financial-incentive programs for smoking cessation. N Engl J Med 372(22):2108–2117CrossRefPubMedPubMedCentral

30.

Stead LF et al (2010) Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev:. doi:10.1002/14651858.cd008286

31.

Whittaker R et al (2007) Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev:. doi:10.1002/14651858.cd006611

32.

McRobbie H et al (2014) Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev:. doi:10.1002/14651858.cd010216.pub2 PubMed

33.

Kalkhoran S, Glantz SA (2016) E‑cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med 4(2):116–128CrossRefPubMed

34.

Nowak D et al (2015) Position paper of the German Respiratory Society (DGP) on electronic cigarettes (E-cigarettes) in cooperation with the following scientific societies and organisations: BVKJ, BdP, DGAUM, DGG, DGIM, DGK, DKG, DGSMP, GPP. Pneumologie 69(3):131–134CrossRefPubMed

35.

Torres A et al (2015) Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax 70(10):984–989CrossRefPubMedPubMedCentral

36.

Moberley S et al (2013) Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev:. doi:10.1002/14651858.cd000422.pub3 PubMed

37.

Tomczyk S et al (2014) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥ 65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 63(37):822–825PubMed

38.

Mirsaeidi M et al (2014) Pneumococcal vaccine and patients with pulmonary diseases. Am J Med 127(9):886.e1–886.e8CrossRef

39.

Pisano J, Cifu AS (2015) Use of pneumococcal vaccine in adults. JAMA 313(7):719–720CrossRefPubMed

40.

Isturiz R, Webber C (2015) Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults. Hum Vaccin Immunother 11(7):1825–1827CrossRefPubMedPubMedCentral

41.

Griffiths TL et al (2000) Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 355(9201):362–368CrossRefPubMed

42.

McCarthy B et al (2015) Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev:. doi:10.1002/14651858.cd003793.pub3

43.

Candemir I et al (2015) Assessment of pulmonary rehabilitation efficacy in chronic obstructive pulmonary disease patients using the chronic obstructive pulmonary disease assessment test. Expert Rev Respir Med 9(4):487–492CrossRefPubMed

44.

Puhan MA et al (2005) Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev:. doi:10.1002/14651858.cd005305

45.

Puhan MA et al (2012) Early versus late pulmonary rehabilitation in chronic obstructive pulmonary disease patients with acute exacerbations: a randomized trial. Respiration 83(6):499–506CrossRefPubMed

46.

Greulich T et al (2015) Effect of a three-week inpatient rehabilitation program on 544 consecutive patients with very severe COPD: a retrospective analysis. Respiration 90(4):287–292CrossRefPubMed

47.

Vieira DS, Maltais F, Bourbeau J (2015) Home-based pulmonary rehabilitation in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 16(2):134–143CrossRef

48.

Marquis N et al (2015) In-home pulmonary telerehabilitation for patients with chronic obstructive pulmonary disease: a pre-experimental study on effectiveness, satisfaction, and adherence. Telemed J E Health 21(11):870–879CrossRefPubMed

49.

Paneroni M et al (2013) Feasibility and effectiveness of an educational program in Italian COPD patients undergoing rehabilitation. Respir Care 58(2):327–333CrossRefPubMed

50.

Paneroni M et al (2015) Is telerehabilitation a safe and viable option for patients with COPD? A feasibility study. COPD 12(2):217–225CrossRefPubMed

51.

Vogelmeier C et al (2011) Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364(12):1093–1103CrossRefPubMed

52.

Wedzicha JA et al (2016) Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 374(23):2222–2234CrossRefPubMed

53.

Woodruff PG et al (2015) Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 385(9979):1789–1798CrossRefPubMedPubMedCentral

54.

Albert RK et al (2011) Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365(8):689–698CrossRefPubMedPubMedCentral

55.

Tashkin DP et al (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359(15):1543–1554CrossRefPubMed

56.

Vogelmeier CF (2014) Possible harms of theophylline in chronic obstructive pulmonary disease. Dtsch Ärztebl Int 111(17):291–292PubMedPubMedCentral

57.

Leuppi JD et al (2013) Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 309(21):2223–2231CrossRefPubMed

58.

Soler N et al (2012) Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD. Eur Respir J 40(6):1344–1353CrossRefPubMed

59.

Troosters T (2013) Chronic obstructive pulmonary disease: exercise training on the edge. Exp Physiol 98(6):1079–1080CrossRefPubMed

60.

Greulich T et al (2014) Benefits of whole body vibration training in patients hospitalised for COPD exacerbations – a randomized clinical trial. BMC Pulm Med 14:60CrossRefPubMedPubMedCentral

61.

Zoumot Z et al (2015) Endobronchial coils for severe emphysema are effective up to 12 months following treatment: medium term and cross-over results from a randomised controlled trial. PLOS ONE 10(4):e0122656CrossRefPubMedPubMedCentral

62.

Eberhardt R et al (2015) Endoscopic lung volume reduction with endobronchial valves in patients with severe emphysema and established pulmonary hypertension. Respiration 89(1):41–48CrossRefPubMed

63.

Eberhardt R et al (2015) Endoscopic bronchial valve treatment: patient selection and special considerations. Int J Chron Obstruct Pulmon Dis 10:2147–2157PubMedPubMedCentral

64.

Klooster K et al (2015) Endobronchial valves for emphysema without Interlobar collateral ventilation. N Engl J Med 373(24):2325–2335CrossRefPubMed

65.

Magnussen H et al (2014) Statement to long term oxygen therapy. Pneumologie 68(9):591–593CrossRefPubMed

66.

Koehler U et al (2014) Long-term oxygen therapy (LTOT) – what should physicians, homecare-providers and health insurance companies know? Pneumologie 68(3):193–198CrossRefPubMed

67.

Lloyd-Owen SJ et al (2005) Patterns of home mechanical ventilation use in Europe: results from the Eurovent survey. Eur Respir J 25(6):1025–1031CrossRefPubMed

68.

Kohnlein T et al (2014) Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med 2(9):698–705CrossRefPubMed

Titel: Übersicht COPD
Diagnostik, Prävention und Therapie
verfasst von: Dr. B. Beutel
T. Greulich
C. Vogelmeier
A. Rembert Koczulla
Publikationsdatum: 09.01.2017
Verlag: Springer Medizin
Schlagwörter: COPD
Lungenemphysem
Theophyllin
COPD-Exazerbation
Spirometrie
Erschienen in: Zeitschrift für Pneumologie / Ausgabe 1/2017
Print ISSN: 2731-7404
Elektronische ISSN: 2731-7412
DOI: https://doi.org/10.1007/s10405-016-0089-3

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Definition, Pathophysiologie und Diagnostik der pulmonalen Hyperinflation

Neuigkeiten zum Asthma-COPD-Overlap-Syndrom (ACOS)

Die extrapulmonalen Auswirkungen der Lungenüberblähung bei COPD

Assessment und Management der Hyperinflation auf der Intensivstation

Mitteilungen des Berufsverbands der Pneumologen in Baden-Württemberg

COPD: Optionen zur Behandlung bei Hyperinflation